8.7
Excellent
376 reviews
- Communication
- 8.8
- Timeliness
- 8.9
- Accuracy
- 7.6
- Staff
- 8.8
- Value
- 8.9
Lynn Gibson
8.9
- - Stability Studies
- - 18 months January 2023 - June 2024
- - Pharmaceutical Company
Reviewed:
Accurate and reliable stability studies, clear reporting.
The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.
Mrs. Rosemary Grant
8.8
- - Biostatistical Design
- - 4 weeks May - June 2023
- - Research Institution
Reviewed:
Excellent biostatistical support, clear and actionable insights.
The biostatistical support provided was top-notch, offering clear and actionable insights that were critical to the success of our study. The team was responsive and worked closely with us to ensure the analysis met our specific needs.
Roman Hansen Jr.
9.3
- - Project Management
- - 10 weeks July - September 2023
- - Biotech Company
Reviewed:
Seamless project management, results exceeded expectations.
Project management was seamless, and the team exceeded our expectations. They handled all aspects of the project with professionalism and efficiency, keeping us informed every step of the way.
Luther Rutherford-Casper
9.1
- - Pharmacovigilance Services
- - Ongoing
- - Pharmaceutical Company
Reviewed:
Highly effective pharmacovigilance services, ensured compliance.
The pharmacovigilance services ensured that our post-market surveillance was compliant and effective. The team was proactive in monitoring and reporting, providing us with peace of mind and ensuring patient safety.
Eleanor Bartell
8.9
- - Regulatory Submission
- - 6 weeks February 2023
- - Biotech Startup
Reviewed:
Professional and knowledgeable, seamless regulatory submission process.
Our regulatory submission was handled with great care and expertise. The process was seamless, and their knowledge of the regulatory landscape was impressive. The team's support was invaluable, and I would not hesitate to use their services again.
Cora O'Reilly-Grimes Sr.
9.1
- - HTA Submission
- - 8 weeks February - March 2024
- - Biotech Company
Reviewed:
Comprehensive and well-executed HTA submission.
The HTA submission was comprehensive and well-executed. The team managed the complexities of the submission process expertly, ensuring that all necessary data was included and well-presented.
Megan Bahringer
5.8
- - Biostatistical Design
- - 6 weeks February - March 2024
- - Research Institution
Reviewed:
Biostatistical analysis lacked depth, missed key insights.
The biostatistical analysis provided was not as thorough as we had hoped. Some key insights were missed, and we had to engage another provider to get the level of detail we needed. The team seemed overworked and under-resourced.
